NGF and Alzheimer disease: Genetic therapy is a substitute approach that has been created:In a phase 1 research lasting 18 months, the delivery of NGF based on the intracerebral injection of genetically altered autologous fibroblasts to create human NGF was investigated in 8 patients with early AD.Despite the fact that two people experienced subcortical haemorrhages during implantation, it was shown that there was a decreased rate of cognitive decline and a higher rate of cortical glucose absorption (Greco et al., 2009; Goutte et al., 2002).